Literature DB >> 17408368

Mapping and analysis of West Nile virus-specific monoclonal antibodies: prospects for vaccine development.

Mark Throsby1, Jan Ter Meulen, Cecile Geuijen, Jaap Goudsmit, John de Kruif.   

Abstract

Seasonal epidemics of West Nile virus (WNV) infection now occur throughout North America, causing clinical symptoms ranging from fever to encephalitis. There are no specific treatment options or licensed vaccines. Several classically developed vaccine candidates are being evaluated in clinical trials. However, questions of safety and/or immunogenicity may limit their usefulness. Mapping of human and murine antibody repertoires against the WNV envelope protein after WNV infection have revealed important insights into the protective immune response against the virus. This review will give an overview of vaccines under development and summarize current data on E-protein antigenicity that could aid in the design of next generation WNV vaccines.

Entities:  

Mesh：

Substances：

Year:  2007        PMID： 17408368     DOI： 10.1586/14760584.6.2.183

Source DB:  PubMed          Journal:  Expert Rev Vaccines        ISSN： 1476-0584            Impact factor:   5.217


  8 in total

1.  Replication-Defective West Nile Virus with NS1 Deletion as a New Vaccine Platform for Flavivirus.

Authors:  Na Li; Ya-Nan Zhang; Cheng-Lin Deng; Pei-Yong Shi; Zhi-Ming Yuan; Bo Zhang
Journal:  J Virol       Date:  2019-08-13       Impact factor: 5.103

2.  CCR5 deficiency is a risk factor for early clinical manifestations of West Nile virus infection but not for viral transmission.

Authors:  Jean K Lim; David H McDermott; Andrea Lisco; Gregory A Foster; David Krysztof; Dean Follmann; Susan L Stramer; Philip M Murphy
Journal:  J Infect Dis       Date:  2010-01-15       Impact factor: 5.226

3.  A hydrogen peroxide-inactivated virus vaccine elicits humoral and cellular immunity and protects against lethal West Nile virus infection in aged mice.

Authors:  Amelia K Pinto; Justin M Richner; Elizabeth A Poore; Pradnya P Patil; Ian J Amanna; Mark K Slifka; Michael S Diamond
Journal:  J Virol       Date:  2012-12-05       Impact factor: 5.103

4.  Immune response to the West Nile virus in aged non-human primates.

Authors:  Anne M Wertheimer; Jennifer L Uhrlaub; Alec Hirsch; Guruprasad Medigeshi; Jerald Sprague; Alfred Legasse; Jennifer Wilk; Clayton A Wiley; Peter Didier; Robert B Tesh; Kristy O Murray; Michael K Axthelm; Scott W Wong; Janko Nikolich-Žugich
Journal:  PLoS One       Date:  2010-12-02       Impact factor: 3.240

Review 5.  Possible future monoclonal antibody (mAb)-based therapy against arbovirus infections.

Authors:  Giuseppe Sautto; Nicasio Mancini; Giacomo Gorini; Massimo Clementi; Roberto Burioni
Journal:  Biomed Res Int       Date:  2013-08-22       Impact factor: 3.411

6.  Vaccine-induced protection of rhesus macaques against plasma viremia after intradermal infection with a European lineage 1 strain of West Nile virus.

Authors:  Babs E Verstrepen; Herman Oostermeijer; Zahra Fagrouch; Melanie van Heteren; Henk Niphuis; Tom Haaksma; Ivanela Kondova; Willy M Bogers; Marina de Filette; Niek Sanders; Linda Stertman; Sofia Magnusson; Orsolya Lőrincz; Julianna Lisziewicz; Luisa Barzon; Giorgio Palù; Michael S Diamond; Stefan Chabierski; Sebastian Ulbert; Ernst J Verschoor
Journal:  PLoS One       Date:  2014-11-13       Impact factor: 3.240

7.  A novel platform for virus-like particle-display of flaviviral envelope domain III: induction of Dengue and West Nile virus neutralizing antibodies.

Authors:  Anthony J S Chua; Cyrielle Vituret; Melvin L C Tan; Gaëlle Gonzalez; Pierre Boulanger; Mah-Lee Ng; Saw-See Hong
Journal:  Virol J       Date:  2013-04-24       Impact factor: 4.099

8.  An Overview of Current Approaches Toward the Treatment and Prevention of West Nile Virus Infection.

Authors:  Dhiraj Acharya; Fengwei Bai
Journal:  Methods Mol Biol       Date:  2016
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.